Alpha Tau Medical (NASDAQ:DRTS) CFO Sells $27,693.54 in Stock

Alpha Tau Medical Ltd. (NASDAQ:DRTS) CFO Raphi Levy sold 2,127 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $13.02, for a total value of $27,693.54. Following the completion of the transaction, the chief financial officer directly owned 90,180 shares in the company, valued at $1,174,143.60. The trade was a 2.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Raphi Levy also recently made the following trade(s):

• On Tuesday, June 30th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $12.00, for a total value of $240,000.00.
• On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The shares were sold at an average price of $11.00, for a total value of $220,000.00.
• On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total value of $167,125.00.
• On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total value of $351,975.00.

Alpha Tau Medical Price Performance

Shares of DRTS stock opened at $13.23 on Friday. The stock’s fifty day moving average is $9.85 and its 200-day moving average is $7.89. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The stock has a market capitalization of $1.20 billion, a PE ratio of -19.75 and a beta of 1.17. Alpha Tau Medical Ltd. has a 52 week low of $2.87 and a 52 week high of $13.23.

Alpha Tau Medical (NASDAQ:DRTS) last announced its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). Equities research analysts expect that Alpha Tau Medical Ltd. will post -0.67 EPS for the current fiscal year.

Institutional Trading of Alpha Tau Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in DRTS. Mariner LLC boosted its stake in shares of Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after purchasing an additional 1,915 shares during the last quarter. Trifecta Capital Advisors LLC bought a new stake in shares of Alpha Tau Medical during the fourth quarter worth approximately $48,000. Envestnet Asset Management Inc. acquired a new position in Alpha Tau Medical in the third quarter valued at approximately $62,000. Wells Fargo & Company MN lifted its holdings in Alpha Tau Medical by 291.7% in the fourth quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after buying an additional 17,500 shares during the period. Finally, Principal Financial Group Inc. bought a new position in Alpha Tau Medical in the first quarter valued at approximately $132,000. 2.65% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DRTS shares. Citigroup upped their target price on shares of Alpha Tau Medical from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, March 11th. Piper Sandler raised their price target on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a report on Tuesday, May 19th. Zacks Research cut shares of Alpha Tau Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Finally, Barclays upped their price objective on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Thursday, June 4th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.60.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.